Lyell Immunopharma price target lowered to $6 from $8 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Lyell Immunopharma to $6 from $8 and keeps a Buy rating on the shares post the Q4 report. Given the recent dynamics and challenges for cell therapy in solid tumors, the firm increased its discount rate.